The waitlist was the advertisement all along

What the MHRA published, and why a waitlist counts#

A fox does not test the fence where the farmer is watching. It works the quiet quarry at the back of the field, the gap in the hedgerow nobody thought to check. Growth teams have run weight loss advertising the same way for two years, treating the pre-launch capture page as plain plumbing rather than promotion, because nothing is being sold yet. This week the regulator walked round the back of that field and closed the gap.

The MHRA released its July 2026 advertising investigations on 5 August as six decision documents rather than six cases, and across them 13 companies are named, nine of them relating to weight loss. The distinction matters, because the shape of the sweep is the story. This is not a single scandal about one bad banner. It is a survey, and most weight loss advertising teams will catch their own scent in it.

Three of the six sit squarely on owned channels: emails, text messages, and join-the-waitlist pages for products holding no UK marketing authorisation. Paid creative is barely the point. The MHRA has gone after the parts of the funnel that marketing teams build, ship and then forget, which is precisely where weight loss advertising risk has quietly accumulated while everyone watched the ad accounts.

Six documents, not six cases#

Read the file properly before repeating it, because the easy summary is wrong. Medex Pharmaceuticals is not a weight loss case at all. Its decision concerns an email to persons qualified to prescribe or supply, promoting Kenalog inconsistently with the summary of product characteristics and possibly lacking required prescribing information. Medex acknowledged the error, stopped the campaign, and reviewed its training and procedures.

The hay fever decision is the other one people miscount. Clinic M Medical and The GP Surgery promoted Kenalog, a prescription only medicine unlicensed for hay fever, to the public as a hay fever injection. Both amended after MHRA action. A sixth document covers The K Clinic and mental-health support. Nine of the thirteen companies relate to weight loss; the other four do not, and lumping them together makes a briefing look sloppy the second a client checks.

The test that catches a waitlist: likely to lead to the use of#

One sentence settles the whole argument. Regulation 284 of the Human Medicines Regulations 2012, in force as at 9 August 2026, says that a person may not publish an advertisement that is likely to lead to the use of a prescription only medicine. That is the operative clause, quoted in full, and it is far wider than most weight loss advertising review processes assume.

So the waitlist is not a loophole in weight loss advertising. A capture page promising early access to something extraordinary, then collecting an email address so it can tell you the moment the thing lands, is a communication engineered to end in the use of a medicine. The absence of a brand name is not a defence. It is the mechanism, and the MHRA has now said so on the record twice in one file.

Menwell Ltd t/a Voy ran social advertisements for Orlos (orlistat) 60mg built on coming soon, a new dawn is coming, a silhouetted pill bottle and an invitation to join the presale waitlist today. The MHRA found breaches of regulations 279 and 280. The advertisements were withdrawn and the company gave a compliance commitment.

Sit with that finding, because it inverts the usual creative instinct. The teaser was judged misleading precisely because it floated free of the product it was promoting. In weight loss advertising, vague is not safe. Vagueness lets a reader fill the gap with the injection they have already seen on social media, and a regulator reads the gap the way the reader does.

Phlo Technologies Ltd t/a Phlo Clinic sent an email to the public inviting consumers to join a waitlist for early access to GLP-1 products with no UK Marketing Authorisation. The MHRA found the email had promotional intent, cited regulation 279, and the email was withdrawn with a compliance commitment attached. No product was on sale. The email was still an advertisement.

The two regulations behind those findings are worth learning properly, and they sit together in Part 14 of the Human Medicines Regulations. Regulation 279 bars advertising a medicinal product that has no marketing authorisation in force. Regulation 280 requires an advertisement to comply with the summary of product characteristics, encourage rational use, present the product objectively without exaggerating its properties, and avoid misleading. Between them they cover the pre-launch tease and the post-launch overclaim.

Trade coverage read the pattern the same way. Chemist and Druggist reported that the majority of the investigations concerned regulation 284, which prohibits the publication of an advertisement to the public that is likely to lead to the use of a POM. That is the sentence to pin above the desk of whoever signs off weight loss advertising in your business.

Two regulators, three weeks, one funnel: the workaround does not work#

Phlo is the sharpest lesson in the set, and it is not really about Phlo. One company was caught twice, by two different regulators, three weeks apart, at two different points in the same funnel. That is the spine of the story for anyone running weight loss advertising with a clinical service behind it.

On 15 July 2026 the ASA upheld a complaint against Phlo Technologies and Wm Morrison Supermarkets over a paid Facebook advertisement for the Morrisons Clinic weight loss service, from £79 a month. The advertisement itself was not the failure. The landing pages behind its filtering page were, because in the ASA's words, consumers who had clicked on either option on the filtering page from the ad were actively presented with POMs. That breached CAP rule 12.12.

Three weeks later the MHRA took the email. Same company, different regulator, different rung of the funnel. If you were building a defence on the idea that the advertisement is the regulated object, both decisions answer in unison: in weight loss advertising the perimeter is the whole path, from the first impression to the page after the page after the click.

The fix is legible, and it turns on what a message promises rather than what it literally says. What follows is illustrative creative written for this piece, not an MHRA exhibit, although it maps closely onto the findings in the Phlo and Voy decisions.

Then there is the workaround set piece, published the very same day. The ASA upheld ruling A26-1337420 against Innate-Essence Ltd t/a The Turmeric Co, whose webpage carried testimonials with words visually blurred, surrounded by legible words including cured, halved and very much reduced.

The page heading read: "Blurry here. Crystal clear on Trustpilot. Regulations mean we can't show everything on this page, but you can read the lot over there." The ASA held that the blurring did not remove the prohibited meaning, and that the heading itself reinforced the implication. Upheld, under CAP Code rules 15.6 and 15.6.2, which bar claims that a food prevents, treats or cures human disease.

Why the rules exist: what weight loss advertising actually does#

It would be easy to file weight loss advertising rules as bureaucratic fussing over adjectives. The evidence says otherwise, and the sharpest number landed a month before the MHRA file did.

Yale researchers ran a secret-shopper study across 49 different websites selling GLP-1 medicines direct to consumers, sending each the same simulated patient, a 27-year-old man who qualified for the drug. According to Yale School of Medicine, 92 per cent of those websites prescribed the medication and 69 per cent mailed it.

The researchers put the finding plainly. Ashwin Chetty said the team knew many people were getting these drugs outside insurance cover, "but we were surprised that the vast majority of these websites did not require communication with a clinician". Reshma Ramachandran added that "telehealth needs to replicate the patient-clinician experience that happens in real-world settings", which is a sentence worth taping to the wall of any growth team building a health funnel.

The paper behind the release is indexed as PMID 42406378, published in JAMA at 336(5):428-431 with doi 10.1001/jama.2026.9131, and its own plain-language summary describes a secret-shopper study of the prescription process and clinical engagement involved in getting GLP-1 receptor agonists from online sellers. The JAMA page also notes that nearly 20 per cent of adults taking a GLP-1 obtain prescriptions online.

The evidence on demand is thinner than the rhetoric#

Be honest about the causal literature, because the other side of the table will be. The standard citation is a systematic review in the Journal of Clinical Psychiatry by Becker and Midoun, which screened 989 articles, read 69 in full text, and included four studies across five manuscripts. Its conclusion is that requests prompted by direct-to-consumer advertising are typically accommodated, promote higher prescribing volume, and have competing effects on treatment quality.

Four studies is a small base, and one of the findings runs the other way: in depression, advertising-prompted requests improved adherence to minimum treatment guidelines. Use that review as the reason the British ban on advertising prescription medicines to the public exists, not as a hammer. The honest version of the argument is more persuasive anyway, and it does not fall over when a client's medical adviser reads the abstract.

The international picture rhymes, because weight loss advertising travels. Korea's Ministry of Food and Drug Safety flagged 26 businesses over deceptive wellness advertising, covering products with 600,000 units sold and worth 11.5 billion won, about 8 million dollars, the Korea JoongAng Daily reported on 6 August 2026. The tactics named include AI-generated before-and-after images, celebrity association and slogans such as edible Wegovy, with advertisers posting then deleting advertisements on social media to dodge detection. Legislation passed in April 2026 banning AI-generated fake experts in advertising takes effect later this year.

The pre-launch funnel audit for weight loss advertising teams#

None of this needs a rebrand. Weight loss advertising needs an inventory, and the inventory has to include the assets nobody in the building calls advertising.

Start from the definition rather than the department. If a communication is likely to lead to the use of a prescription only medicine, it is in scope, whoever built it and whichever budget line paid for it. That sweeps in lifecycle emails, SMS flows, waitlist pages, referral mechanics, app push, affiliate copy and the influencer brief nobody kept a copy of.

Notice that every step there is a marketing control rather than a legal one. Legal can hand you the test. Only the team holding the email platform, the CMS and the ad accounts can say what is actually going out, and most of that traffic leaves tracks nobody has read. Building the list is unglamorous work done back at the den, and it is the work that decides who is still trading in this category in 2028.

That inventory is the first thing folkfox healthcare marketing does on any regulated account, and the same discipline runs through content marketing and paid social, where the compliant asset has to be the one that performs. The adjacent lessons are already written up: the funnel as a health record, what pixel settlements really cost, the FTC running the same argument, and how compliant health content earns citations.

There is a warmer read here, and it is worth taking. The MHRA has told the sector that the quiet parts of the funnel are the real advertisement, which hands the people who write those quiet parts an authority they did not have last week. Weight loss advertising built on a waitlist was always a fragile trail to follow. Weight loss advertising built on a clear service, a stated price and a real eligibility conversation is duller, sturdier, and considerably harder to withdraw.

Frequently asked questions#